NFE2L3 upregulates IL33 and inhibits RAB27A, thereby promoting mast cell activation sand the release of inflammatory factors, creating a pro-cancer inflammatory microenvironment; it can also directly regulate the cell cycle to promote the proliferation of CRC cells (Saliba et al., 2022). This evidence concerns the gene IL33 and cancer.